1、 PINTER M, ULBRICH G, SIEGHART W, et al. Hepatocellular carcinoma:a phase ii randomized controlled double blind trial of transarterial chemoembolization in combination with biweekly intravenous administration of bevacizumab or a placebo[J]. Radiol, 2015, 277(3): 903-912. PINTER M, ULBRICH G, SIEGHART W, et al. Hepatocellular carcinoma:a phase ii randomized controlled double blind trial of transarterial chemoembolization in combination with biweekly intravenous administration of bevacizumab or a placebo[J]. Radiol, 2015, 277(3): 903-912.
2、 BRITTEN C D, GOMES A S, WAINBERG Z A, et al. Transarterial chemoembolization plus or minus intravenous bevacizumab in the treatment of hepatocellular cancer: a pilot study[J]. BMC Cancer, 2012(1): 12-16. BRITTEN C D, GOMES A S, WAINBERG Z A, et al. Transarterial chemoembolization plus or minus intravenous bevacizumab in the treatment of hepatocellular cancer: a pilot study[J]. BMC Cancer, 2012(1): 12-16.
3、 WANG J K, ZHOU Y Y, GUO S J, et al. Cetuximab conjugated and doxorubicin loaded silica nanoparticles for tumor-targeting and tumor microenvironment responsive binary drug delivery of liver cancer therapy[J]. Mate Sci Eng C, 2017(76): 944-950. WANG J K, ZHOU Y Y, GUO S J, et al. Cetuximab conjugated and doxorubicin loaded silica nanoparticles for tumor-targeting and tumor microenvironment responsive binary drug delivery of liver cancer therapy[J]. Mate Sci Eng C, 2017(76): 944-950.
4、 BUIJS M, REYES D K, PAWLIK T M, et al. Phase 2 trial of concurrent Bevacizumab and transhepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma[J]. Cancer, 2013, 119(5): 1042-1049. BUIJS M, REYES D K, PAWLIK T M, et al. Phase 2 trial of concurrent Bevacizumab and transhepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma[J]. Cancer, 2013, 119(5): 1042-1049.
5、 SPENCER P H,BISHAL G,ELVIRA D, et al. A systematic review and meta-analysis of bevacizumab in first-line metastatic breast cancer: lessons for the research and regulatory enterprises[J]. Natl Cancer, 2020,112(4): djz211. SPENCER P H,BISHAL G,ELVIRA D, et al. A systematic review and meta-analysis of bevacizumab in first-line metastatic breast cancer: lessons for the research and regulatory enterprises[J]. Natl Cancer, 2020,112(4): djz211.
6、 SHOJI T, ETO H, SATO T, et al. A new therapeutic strategy for recurrent ovarian cancer-bevacizumab beyond progressive disease[J]. Healthcare (Basel), 2019, 7(3): E109. SHOJI T, ETO H, SATO T, et al. A new therapeutic strategy for recurrent ovarian cancer-bevacizumab beyond progressive disease[J]. Healthcare (Basel), 2019, 7(3): E109.
7、 KUDO M, UESHIMA K, TORIMURA T, et al. Randomized, open label, multicenter, phase II trial of transcatheter arterial chemoembolization (TACE) therapy in combination with sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial[J]. Clin Oncol, 2018(36): 206. KUDO M, UESHIMA K, TORIMURA T, et al. Randomized, open label, multicenter, phase II trial of transcatheter arterial chemoembolization (TACE) therapy in combination with sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial[J]. Clin Oncol, 2018(36): 206.
8、 ZHAN P, QIAN Q, YU L K. Serum VEGF level is associated with the outcome of patients with hepatocellular carcinoma: a meta-analysis[J]. Hepatobiliary Surg, 2013(2): 209-215. ZHAN P, QIAN Q, YU L K. Serum VEGF level is associated with the outcome of patients with hepatocellular carcinoma: a meta-analysis[J]. Hepatobiliary Surg, 2013(2): 209-215.
9、 VIVEIROS P, RIAZA, LEWANDOWSKI R J, et al. Current state of liver directed therapies and combinatory approaches with systemic therapy in hepatocellular carcinoma (HCC) [J]. Cancers (Basel), 2019, 11(8): E1085. VIVEIROS P, RIAZA, LEWANDOWSKI R J, et al. Current state of liver directed therapies and combinatory approaches with systemic therapy in hepatocellular carcinoma (HCC) [J]. Cancers (Basel), 2019, 11(8): E1085.
10、 PANG R, POON R T. Angiogenesis and antiangiogenic therapy in hepatocellular carcinoma[J]. Cancer Lett, 2006, 242(2): 151-167. PANG R, POON R T. Angiogenesis and antiangiogenic therapy in hepatocellular carcinoma[J]. Cancer Lett, 2006, 242(2): 151-167.
11、 FERNáNDEZ M, SEMELA D, BRUIX J, et al. Angiogenesis in liver disease[J]. Hepatol, 2009(50): 604-620. FERNáNDEZ M, SEMELA D, BRUIX J, et al. Angiogenesis in liver disease[J]. Hepatol, 2009(50): 604-620.
12、 SAKURAI Y, OHGIMOTO K, KATAOKA Y. Essential role of Flk-1 (VEGF receptor 2) tyrosine residue 1173 in vasculogenesis in mice[J]. Proc Natl Acad Sci USA, 2005, 102(4): 1076-1081. SAKURAI Y, OHGIMOTO K, KATAOKA Y. Essential role of Flk-1 (VEGF receptor 2) tyrosine residue 1173 in vasculogenesis in mice[J]. Proc Natl Acad Sci USA, 2005, 102(4): 1076-1081.
13、 NAHM J H, RHEE H, KIM H, et al. Increased expression of stemness markers and altered tumor stroma in hepatocellular carcinoma under TACE-induced hypoxia: a biopsy and resection matched study[J]. Oncotarget, 2017(8): 99359-99371. NAHM J H, RHEE H, KIM H, et al. Increased expression of stemness markers and altered tumor stroma in hepatocellular carcinoma under TACE-induced hypoxia: a biopsy and resection matched study[J]. Oncotarget, 2017(8): 99359-99371.
14、 XIAO E H, GUO D, BIAN D J. Effect of preoperative transcatheter arterial chemoembolization on angiogenesis of hepatocellular carcinoma cells[J]. World J Gastroenterol, 2009(15): 4582-4586. XIAO E H, GUO D, BIAN D J. Effect of preoperative transcatheter arterial chemoembolization on angiogenesis of hepatocellular carcinoma cells[J]. World J Gastroenterol, 2009(15): 4582-4586.
15、 钱骏, 冯敢生. 原发性肝癌的综合介入治疗[J]. 中华肿瘤杂志, 2003, 25(5): 417-420. 钱骏, 冯敢生. 原发性肝癌的综合介入治疗[J]. 中华肿瘤杂志, 2003, 25(5): 417-420.
16、 BRUIX J, SHERMAN M. Practice guidelines committee, American association for the study of liver diseases. management of hepatocellular carcinoma[J]. Hepatol, 2005(42): 1208-1236. BRUIX J, SHERMAN M. Practice guidelines committee, American association for the study of liver diseases. management of hepatocellular carcinoma[J]. Hepatol, 2005(42): 1208-1236.
17、 岳希鹏, 李瀛, 别良玉, 等. 贝伐单抗对接受TACE治疗的晚期肝癌患者疗效的影响[J]. 河南医学研究杂志, 2018, 27(24): 4439-4442. 岳希鹏, 李瀛, 别良玉, 等. 贝伐单抗对接受TACE治疗的晚期肝癌患者疗效的影响[J]. 河南医学研究杂志, 2018, 27(24): 4439-4442.
18、 孙健铭, 杨彦林, 王继光. 贝伐单抗联合TACE治疗原发性肝癌近远期疗效评价[J]. 实用药物与临床杂志, 2018, 21(10): 1120-1123. 孙健铭, 杨彦林, 王继光. 贝伐单抗联合TACE治疗原发性肝癌近远期疗效评价[J]. 实用药物与临床杂志, 2018, 21(10): 1120-1123.
19、 孙健. 贝伐单抗联合肝动脉化疗栓塞术对原发性肝癌患者生存期 的影响研究[J]. 医药天地杂志, 2018, 15(8): 76-77. 孙健. 贝伐单抗联合肝动脉化疗栓塞术对原发性肝癌患者生存期 的影响研究[J]. 医药天地杂志, 2018, 15(8): 76-77.
20、 曾筱怡, 邱金宝, 陈林.贝伐单抗联合肝动脉化疗栓塞术 对36 例晚期原发性肝癌生存预后的影响分析[J]. 药物临床杂志, 2016, 37(19): 20-23,57. 曾筱怡, 邱金宝, 陈林.贝伐单抗联合肝动脉化疗栓塞术 对36 例晚期原发性肝癌生存预后的影响分析[J]. 药物临床杂志, 2016, 37(19): 20-23,57.
21、 赵灵华, 曾斌. 贝伐单抗联合肝动脉化疗栓塞术治疗原发性肝癌的临床疗效及安全性评[J]. 中国临床药理学杂志, 2016, 32(2): 126-128. 赵灵华, 曾斌. 贝伐单抗联合肝动脉化疗栓塞术治疗原发性肝癌的临床疗效及安全性评[J]. 中国临床药理学杂志, 2016, 32(2): 126-128.
22、 马红丹, 万灵侠, 王春燕. 贝伐单抗联合肝动脉化疗栓塞术治疗原发性肝癌疗效分析[J]. 医药论坛杂志, 2016, 37(10): 129-131. 马红丹, 万灵侠, 王春燕. 贝伐单抗联合肝动脉化疗栓塞术治疗原发性肝癌疗效分析[J]. 医药论坛杂志, 2016, 37(10): 129-131.
23、 JADAD A R, MOORE R A, CARROLL D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary[J]. Control Clin Trials, 1996, 17(1): 1-12. JADAD A R, MOORE R A, CARROLL D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary[J]. Control Clin Trials, 1996, 17(1): 1-12.
24、 CONG J, LIU R, HOU J, et al. Therapeutic effect of bevacizumab combined with paclitaxel and carboplatin on recurrent ovarian cancer[J]. J BUON, 2019, 24(3): 1003-1008. CONG J, LIU R, HOU J, et al. Therapeutic effect of bevacizumab combined with paclitaxel and carboplatin on recurrent ovarian cancer[J]. J BUON, 2019, 24(3): 1003-1008.
25、 FLORESCU-TENEA R M, KAMAL A M, ITRUT P M, et al. Colorectal Cancer: an update on treatment options and future perspectives[J]. Curr Health Sci J, 2019, 45(2): 134-141. FLORESCU-TENEA R M, KAMAL A M, ITRUT P M, et al. Colorectal Cancer: an update on treatment options and future perspectives[J]. Curr Health Sci J, 2019, 45(2): 134-141.
26、 ROVIELLO G, BACHELOT T, HUDIS C A, et al. The role of bevacizumab in solid tumours: a literature based meta-analysis of randomised trials[J]. Eur J Cancer, 2017(75): 245-258. ROVIELLO G, BACHELOT T, HUDIS C A, et al. The role of bevacizumab in solid tumours: a literature based meta-analysis of randomised trials[J]. Eur J Cancer, 2017(75): 245-258.
27、 LI X, FENG G S, ZHENG C S, et al. Expression of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma and effect of transcatheter arterial chemoembolization therapy on plasma vascular endothelial growth factor level[J]. World J Gastroenterol, 2004,(10): 2878-2882. LI X, FENG G S, ZHENG C S, et al. Expression of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma and effect of transcatheter arterial chemoembolization therapy on plasma vascular endothelial growth factor level[J]. World J Gastroenterol, 2004,(10): 2878-2882.
28、 FINN R S, ZHU A X. Targeting angiogenesis in hepatocellular cancer: focus on VEGF and bevacizumab[J]. Expert Rev Anticancer Ther, 2009(9): 503-509. FINN R S, ZHU A X. Targeting angiogenesis in hepatocellular cancer: focus on VEGF and bevacizumab[J]. Expert Rev Anticancer Ther, 2009(9): 503-509.
29、 GEORGIADES C S, HONG K, GESCHWIND J F. Radiofrequency ablation and chemoembolization for hepatocellular carcinoma[J]. Cancer J, 2008, 14(2): 117-122. GEORGIADES C S, HONG K, GESCHWIND J F. Radiofrequency ablation and chemoembolization for hepatocellular carcinoma[J]. Cancer J, 2008, 14(2): 117-122.
30、 SARASWAT V A, PANDEY G, SHETTY S. Treatment algorithms for managing hepatocellular carcinoma[J]. J Clin Exp Hepatol, 2014, 4(Suppl 3): S80-89. SARASWAT V A, PANDEY G, SHETTY S. Treatment algorithms for managing hepatocellular carcinoma[J]. J Clin Exp Hepatol, 2014, 4(Suppl 3): S80-89.
31、 BRUIX J, SHERMAN M. Management of hepatocellular carcinoma[J]. Hepatol, 2005(42): 1208-1236. BRUIX J, SHERMAN M. Management of hepatocellular carcinoma[J]. Hepatol, 2005(42): 1208-1236.
32、 MATTIUZZI C, LIPPI G. Current Cancer Epidemiology[J]. Epidemiol Glob Health, 2019,9(4):217-222. MATTIUZZI C, LIPPI G. Current Cancer Epidemiology[J]. Epidemiol Glob Health, 2019,9(4):217-222.
33、 BRAY F, FERLAY J, SOERJOMATARAM I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424. BRAY F, FERLAY J, SOERJOMATARAM I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424.
34、 FENG R M, ZONG Y N, CAO S M, et al. Currentcancer situation in China: good or bad news from the 2018 Global Cancer Statistics? [J]. Cancer Commun (Lond), 2019, 39(1): 22. FENG R M, ZONG Y N, CAO S M, et al. Currentcancer situation in China: good or bad news from the 2018 Global Cancer Statistics? [J]. Cancer Commun (Lond), 2019, 39(1): 22.
